Pfizer Hit With Bextra Lawsuit
Pfizer also is negotiating with the Food and Drug Administration for a tougher label on Bextra, which has been linked to the rare skin rash called Stevens-Johnson Syndrome. The company said in a recent filing with the Securities and Exchange Commission that a revised Bextra label "likely will include the addition of a black-box" warning about the skin disease. The black box warning is the FDA's strongest warning. The current Bextra label alerts doctors and patients to this side-effect. This warning was inserted in 2002, a year after Bextra was approved by the FDA.
Ever since Merck pulled Vioxx from the market, Pfizer has released several studies showing no cardiovascular risk for Celebrex, its best-selling COX-2 drug. Pfizer recently said it would conduct tests assessing the long-term cardiovascular impact of Celebrex. Pfizer's stock lost 27 cents, or 1%, to $27.35, just above its 52-week low of $27.02- Loading Comments...
- Loading Comments...
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,270.47 | 1,093.48 | 2,167.88 | 34.29 |
Oil *
75.55
|
|
UP
73.00
|
UP
6.24
|
UP
18.86
|
DOWN
0.17
|
10 Yr
3.43%
SPDR Gold
109.74
|
|
+0.72%
|
+0.57%
|
+0.88%
|
-0.49%
|
Data delayed 20 minutes |














